Exclusive: Cancer drugmaker Tesaro attracts takeover interest - sources
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq futures surge 2% as chip outlook calms AI jitters; inflation data awaited
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Leerink Partners Downgrades Tesaro (TSRO) to Market Perform
February 10, 2017 6:51 AM ESTLeerink Partners downgraded Tesaro (NASDAQ: TSRO) from Outperform to Market Perform with a price target of $186.00 (from $152.00).
For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.
Shares of Tesaro closed at $186.91 yesterday.
... MoreTESARO (TSRO) may be worth $250/share in sale, Bloomberg citing SunTrust
February 8, 2017 1:07 PM ESTTESARO (NASDAQ: TSRO) may be worth $250/share in sale, Bloomberg citing SunTrust.
... More